An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Adverse reactions
- Sponsors Ultragenyx Pharmaceutical
- 18 Apr 2017 Planned End Date changed from 1 Dec 2020 to 1 Sep 2018.
- 18 Apr 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Sep 2018.
- 12 Nov 2015 New trial record